Drug Profile


Alternative Names: Boxeprazine; GBR-12909

Latest Information Update: 19 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gist-Brocades
  • Developer Laguna Pharmaceuticals; Novo Nordisk
  • Class Antidepressants; Antiparkinsonians; Piperazines; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Cocaine abuse; Major depressive disorder; Parkinson's disease; Peptic ulcer

Most Recent Events

  • 04 Dec 2015 Discontinued - Phase-III for Atrial fibrillation in USA, Bulgaria, Hungary, Israel, Netherlands, Poland and Russia (PO)
  • 01 Sep 2015 Phase-III clinical trials in Atrial fibrillation in USA, Russia, Israel, Bulgaria, Hungary (PO)
  • 06 Jun 2015 Laguna Pharmaceuticals plans a phase III trial in Atrial fibrillation in USA (NCT02454283)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top